Investor Presentation Q1 2023
126
Investor presentation
First three months of 2023
North America Operations at a glance.
NAO
Million
70
76
Diabetes trend in population
10%
60
11%
800
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
DKK
billion
First quarter of
2023
Sales
(MDKK)
Growth²
Total GLP-13
17,978
50%
80%
Long-acting insulin
1,153
-32%
5230
40
Premix insulin5
139
-18%
600
60%
GLP-1
Fast-acting insulin6
1,751
-5%
43.7%¹
Human insulin
363
-14%
Insulin
63
Total insulin
57
400
40%
3,406
-18%
51
Other Diabetes care?
161
-30%
2.3%¹
Diabetes care
200
20%
21,545
32%
10
0
2021
OAD
Obesity care8
5,911
156%
17.0%1
0
0%
Diabetes & Obesity
Feb
Feb
27,456
47%
2030
2045
care
2018
2023
Population with diabetes
Diabetes growth rate
Rare disease⁹
1,841
-14%
Total
29,297
41%
GLP-1 MS
-Insulin MS
OAD MS
International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period
Competitor insulin value market shares, as of Feb 2023: Novo
Nordisk 43%, Eli Lilly 30% and Sanofi 25%; Competitor GLP-1
value market shares, as of Feb 2023: Novo Nordisk 53%, Eli Lilly
46% and AstraZeneca 1%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT,
Feb 2023 value figures
2 At constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and Levemir®; 5 Comprises NovoMix®;
6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises Novo NormⓇ and needles; 8
Comprises SaxendaⓇ and WegovyⓇ9 Comprises primarily NovoSevenⓇ,
Novo Eight® Esperoct®, NovoThirteen®, Refixia®, Norditropin®, VagifemⓇ and
Activelle®View entire presentation